Table 5.
Features | MDS (n = 7) | MDS/MPN (n = 5) | AML (n = 4) |
---|---|---|---|
Median survival (range) (month) | 28 (10.5–75) | 31.5 (31–32) | 9 (2–12) |
Leukemic transformation | 43% | 20% | N/A |
Median interval of disease progression (month) | 7.75 | 29 | N/A |
MDS: myelodysplastic syndrome; MDS/MPN: myelodysplastic/myeloproliferative neoplasms; AML: acute myeloid leukemia; N/A: not applicable.